MBCOF (Marvel Biosciences) EBITDA Margin %: 0.00% (As of Apr. 2026)


MBCOF Marvel Biosciences Corp MBCOF
33 GF Score
Price $0.12
! 1 Warning Sign
View Full Analysis

What is Marvel Biosciences EBITDA Margin %?

Marvel Biosciences MBCOF +4.74% 33 EBITDA Margin % is 0.00% as of Apr. 2026. GuruFocus rates MBCOF with a GF Score™ of 33/100. The stock has 1 warning sign investors should review. Among 945 Biotechnology companies, Marvel Biosciences ranks worse than 105820% on this metric.

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Marvel Biosciences's EBITDA for the three months ended in Apr. 2026 was $0.35 Mil. Marvel Biosciences's Revenue for the three months ended in Apr. 2026 was $0.00 Mil. Therefore, Marvel Biosciences's EBITDA margin for the quarter that ended in Apr. 2026 was 0.00%.

Marvel Biosciences  (OTCPK:MBCOF) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.

Marvel Biosciences EBITDA Margin % Related Terms

Marvel Biosciences EBITDA Margin % Historical Data

* Premium members only.

The historical data trend for Marvel Biosciences's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Marvel Biosciences EBITDA Margin % Chart

Marvel Biosciences Annual Data
Trend Jul20 Jul21 Jul22 Jul23 Jul24 Jul25
EBITDA Margin %
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

Marvel Biosciences Quarterly Data
Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24 Oct24 Jan25 Apr25 Jul25 Oct25 Jan26 Apr26
EBITDA Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

MBCOF vs VRTX, REGN, ALNY: EBITDA Margin % Comparison

For the Biotechnology subindustry, Marvel Biosciences's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Marvel Biosciences EBITDA Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Marvel Biosciences's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Marvel Biosciences's EBITDA Margin % falls into.


MBCOF
33GF Score
Marvel Biosciences Corp MBCOF
EBITDA Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Marvel Biosciences EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Marvel Biosciences's EBITDA Margin % for the fiscal year that ended in Jul. 2025 is calculated as

EBITDA Margin %=EBITDA (A: Jul. 2025 )/Revenue (A: Jul. 2025 )
=-1.419/0
= %

Marvel Biosciences's EBITDA Margin % for the quarter that ended in Apr. 2026 is calculated as

EBITDA Margin %=EBITDA (Q: Apr. 2026 )/Revenue (Q: Apr. 2026 )
=0.347/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBITDA Margin % →
What does a EBITDA Margin % of 0.00% mean?
Marvel Biosciences (MBCOF) has a EBITDA Margin % of 0.00% as of Apr. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Marvel Biosciences and its competitors. According to the industry distribution chart, Marvel Biosciences ranks #999999 out of 945 companies in the Biotechnology industry.
Is Marvel Biosciences' EBITDA Margin % too high?
Marvel Biosciences' current EBITDA Margin % is 0.00%. Based on the distribution chart, Marvel Biosciences ranks #999999 out of 945 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Marvel Biosciences has a GF Score™ of 33/100, reflecting its overall financial health beyond just this single metric.
How does Marvel Biosciences' EBITDA Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Marvel Biosciences ranks #999999 out of 945 companies for EBITDA Margin %. This places Marvel Biosciences in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Marvel Biosciences and its competitors. Marvel Biosciences's current EBITDA Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Marvel Biosciences stock overvalued right now?
Marvel Biosciences (MBCOF) has a current EBITDA Margin % of 0.00%. The current EBITDA Margin % is 0.00%. Marvel Biosciences' overall GF Score™ is 33/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Marvel Biosciences (MBCOF), the current EBITDA Margin % is 0.00% as of Apr. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Marvel Biosciences Business Description

Other Exchanges MRVL:Canada
Address 505 - 8th Avenue SW, Suite 420, Calgary, AB, CAN, T2P1G2
Marvel Biosciences Corp is a biotechnology company incorporated in Canada. The Company is currently a pre-clinical stage pharmaceutical development company that utilizes a drug redevelopment approach to identify and evaluate potential therapeutic compounds. Its activities mainly involve scientific research and pre-clinical studies aimed at determining viable active compounds for further drug development.
33GF Score

Get the complete analysis for MBCOF

EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.12
Price